ClinConnect ClinConnect Logo
Search / Trial NCT00966355

Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding

Launched by KOREA UNIVERSITY · Aug 25, 2009

Trial Information

Current as of June 10, 2025

Completed

Keywords

Cirrhosis, Esophagus Disorders, Varicose Veins

ClinConnect Summary

In patients who are suspected to have variceal bleedings, pharmacologic therapy with vasoactive drugs such as terlipressin, somatostatin, and octreotide is recommended as soon as possible, even before endoscopy. However, it is still unclear whether the efficacies of these drugs are same or not. This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • liver cirrhosis
  • age between 16 and 75 years
  • Patients who have upper GI bleeding symptoms (hematemesis or melena) within 24 hours before enrollment
  • Patients whose systolic blood pressure \<100 mmHg or pulse rate \>100/min at the enrollment
  • Patients who were not performed endoscopic or pharmacologic therapy for varices
  • Signed informed consent
  • Exclusion Criteria:
  • Pregnancy
  • Positive anti-HIV Ab
  • A history of severe side-effects or contraindications to study drugs
  • Severe cardiovascular diseases: acute myocardial infarction, A-V block, congestive heart failure, ischemic heart disease, hypertension (systolic blood pressure \>170 mmHg or diastolic pressure \>100 mmHg)
  • Chronic renal failure
  • Hepatocellular carcinoma with protal vein thrombosis
  • Coexisting malignancy except hepatocellular carcinoma

About Korea University

Korea University is a prestigious academic institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Korea University leverages its extensive resources and expertise to conduct innovative studies aimed at enhancing healthcare outcomes. The university fosters collaboration among leading researchers, medical professionals, and industry partners to drive the development of new therapies and interventions. With a focus on ethical standards and patient safety, Korea University is dedicated to contributing valuable insights to the scientific community and improving the quality of life for patients both locally and globally.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Soon Ho Um, Prof

Principal Investigator

Korea University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials